CR8992A - Analogos de biaril piperazinilpiridina sustituida - Google Patents

Analogos de biaril piperazinilpiridina sustituida

Info

Publication number
CR8992A
CR8992A CR8992A CR8992A CR8992A CR 8992 A CR8992 A CR 8992A CR 8992 A CR8992 A CR 8992A CR 8992 A CR8992 A CR 8992A CR 8992 A CR8992 A CR 8992A
Authority
CR
Costa Rica
Prior art keywords
piperazinilpiridina
biaril
analogos
replaced
binders
Prior art date
Application number
CR8992A
Other languages
English (en)
Inventor
A Blum Charles
Brielmann Harry
L Chenard Bertrand
Zheng Xiaozhang
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of CR8992A publication Critical patent/CR8992A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proveen analogas de biaril piperazinil-piridina sustituidos, en donde las variables son como ya se ha descripto en la presente. Tales compuestos son ligantes que pueden utilizarse para modular la actividad de un receptor especifico in vivo o in vitro, y que son particularmente utiles en el tratamiento de cuadros asociados con la activacion patologica de los receptores en seres humanos, animales domesticos y ganado. Tambien se proporcionan las composiciones farmaceuticas y los metodos para usar dichos compuestos en el tratamiento de esos desordenes, asi como metodos para usar dichos ligantes para estudios de localizacion de receptores.
CR8992A 2004-08-13 2007-03-13 Analogos de biaril piperazinilpiridina sustituida CR8992A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60172104P 2004-08-13 2004-08-13
US64179605P 2005-01-05 2005-01-05

Publications (1)

Publication Number Publication Date
CR8992A true CR8992A (es) 2007-08-14

Family

ID=36000525

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8992A CR8992A (es) 2004-08-13 2007-03-13 Analogos de biaril piperazinilpiridina sustituida

Country Status (24)

Country Link
US (2) US7662830B2 (es)
EP (1) EP1786800B1 (es)
JP (1) JP4955554B2 (es)
KR (1) KR20070046924A (es)
CN (1) CN101014587B (es)
AR (1) AR050194A1 (es)
BR (1) BRPI0514319A (es)
CA (1) CA2577301C (es)
CR (1) CR8992A (es)
EC (1) ECSP077318A (es)
HN (1) HN2007006799A (es)
IL (1) IL181040A0 (es)
MA (1) MA28857B1 (es)
MX (1) MX2007001696A (es)
MY (1) MY145822A (es)
NI (1) NI200700040A (es)
NO (1) NO20071243L (es)
NZ (1) NZ553388A (es)
PE (1) PE20060620A1 (es)
RU (1) RU2413726C2 (es)
SG (1) SG157399A1 (es)
TW (1) TW200605889A (es)
WO (1) WO2006026135A2 (es)
ZA (1) ZA200701530B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176437A1 (en) 2001-08-31 2003-09-18 D.M. Watterson Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death
AU2004257289A1 (en) * 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
MY145822A (en) * 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
ES2441718T3 (es) 2004-11-02 2014-02-06 Northwestern University Compuestos de piridazina, composiciones y métodos
WO2006050359A2 (en) 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
AU2005317176A1 (en) * 2004-12-13 2006-06-22 Neurogen Corporation Piperazinyl-pyridine analogues
CA2595205A1 (en) * 2005-01-19 2006-07-27 Neurogen Corporation Heteroaryl substituted piperazinyl-pyridine analogues
CN101754762A (zh) * 2006-04-28 2010-06-23 西北大学 用于治疗神经炎症性疾病的包含哒嗪化合物的制剂
EP2015750A2 (en) 2006-04-28 2009-01-21 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2008057300A2 (en) * 2006-10-27 2008-05-15 Redpoint Bio Corporation Trpvi antagonists and uses thereof
PL2142529T3 (pl) * 2007-04-27 2014-06-30 Purdue Pharma Lp Antagoniści trpv1 i ich zastosowania
US8343966B2 (en) * 2008-01-11 2013-01-01 Novartis Ag Organic compounds
CN103501610A (zh) * 2011-03-09 2014-01-08 西建阿维拉米斯研究公司 Pi3激酶抑制剂和其用途
ES2390326B1 (es) * 2011-04-05 2013-08-14 Universidad Miguel Hernández De Elche Antagonistas de trpv1 y sus usos.
KR20140069235A (ko) 2011-09-27 2014-06-09 노파르티스 아게 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
WO2013079668A1 (en) * 2011-12-02 2013-06-06 Boehringer Ingelheim International Gmbh Piperidine derivatives, pharmaceutical compositions and uses thereof
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
MX355945B (es) 2013-03-14 2018-05-07 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
WO2015014836A1 (en) 2013-07-30 2015-02-05 Janssen R&D Ireland Substituted pyridine-piperazinyl analogues as rsv antiviral compounds
CN115060832B (zh) * 2022-08-18 2022-11-29 上海奥科达生物医药科技有限公司 奥卡西平口服混悬液中奥卡西平及防腐剂含量检测方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4921148B1 (es) 1970-12-28 1974-05-30
US3775326A (en) 1972-04-17 1973-11-27 Addressograph Multigraph Pressure fixable electroscopic printing powder
FR2262512A1 (en) 1974-03-01 1975-09-26 Synthelabo 2,4,6-Tri-substd. -1,3,5-triazines - with analgesic and psychotropic activity
DE2643753A1 (de) 1976-09-29 1978-04-06 Thomae Gmbh Dr K Neue 1h-pyrazolo eckige klammer auf 3,4-b eckige klammer zu pyridine
FI70411C (fi) * 1980-12-29 1986-09-19 Pfizer Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat
DE3609596A1 (de) * 1986-03-21 1987-10-01 Hoechst Ag 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
GB9012311D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
EP0555478A4 (en) 1990-08-31 1993-11-18 Nippon Shinyaku Company, Limited Pyrimidine derivative and medicine
KR970704444A (ko) 1994-08-08 1997-09-06 아만 히데아키 트리아진 유도체 및 의약(triazine derivative and medicine)
US5962453A (en) 1995-08-08 1999-10-05 Nippon Shinyaku Co. Ltd. Triazine derivative and medicine
AR038955A1 (es) 1996-12-05 2005-02-02 Amgen Inc Compuestos de pirimidinona y piridona sustituidos y metodos para su uso
US6489344B1 (en) 1998-06-19 2002-12-03 Chiron Corporation Inhibitors of glycogen synthase kinase 3
DE19836697A1 (de) 1998-08-13 2000-02-17 Hoechst Marion Roussel De Gmbh Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
CA2366858A1 (en) * 1999-04-01 2000-10-12 Margaret Yuhua Chu-Moyer Sorbitol dehydrogenase inhibitors
EP1136483A1 (en) 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-[Piperazinyl]pyrimidone derivatives
WO2001070728A1 (en) * 2000-03-23 2001-09-27 Sanofi-Synthelabo 2-[nitrogen-heterocyclic]pyrimidone derivatives
AU6871801A (en) * 2000-06-29 2002-01-14 Abbott Lab Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
CN1443170A (zh) * 2000-07-20 2003-09-17 神经原公司 辣椒素受体配体
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
EP1247809A3 (en) 2001-03-30 2003-12-17 Pfizer Products Inc. Triazine compounds useful as sorbitol dehydrogenase inhibitors
CN1245391C (zh) 2001-06-01 2006-03-15 弗·哈夫曼-拉罗切有限公司 用作谷氨酸受体的嘧啶、三嗪和吡嗪衍生物
WO2004000820A2 (en) 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
CA2507100C (en) * 2002-11-21 2012-10-09 Chiron Corporation 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
CA2531401A1 (en) 2003-07-10 2005-01-27 Neurogen Corporation Substituted heterocyclic diarylamine analogues
AU2004257289A1 (en) 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
CA2533397A1 (en) 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
MY145822A (en) * 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
AU2005317176A1 (en) 2004-12-13 2006-06-22 Neurogen Corporation Piperazinyl-pyridine analogues
CA2595205A1 (en) 2005-01-19 2006-07-27 Neurogen Corporation Heteroaryl substituted piperazinyl-pyridine analogues
US8258143B2 (en) * 2006-06-28 2012-09-04 Duquesne University Of The Holy Ghost Methods of using substituted pyrrolo[2,3-d]pyrimidines for targeting tumor cells and treating cancer

Also Published As

Publication number Publication date
EP1786800B1 (en) 2017-01-04
ZA200701530B (en) 2008-11-26
JP2008509932A (ja) 2008-04-03
AR050194A1 (es) 2006-10-04
MA28857B1 (fr) 2007-09-03
CA2577301C (en) 2014-05-27
KR20070046924A (ko) 2007-05-03
MY145822A (en) 2012-04-30
EP1786800A4 (en) 2009-05-06
HN2007006799A (es) 2010-11-03
RU2413726C2 (ru) 2011-03-10
IL181040A0 (en) 2007-07-04
JP4955554B2 (ja) 2012-06-20
BRPI0514319A (pt) 2008-06-10
US8334382B2 (en) 2012-12-18
NI200700040A (es) 2008-04-01
NZ553388A (en) 2011-01-28
CA2577301A1 (en) 2006-03-09
WO2006026135A2 (en) 2006-03-09
RU2007106042A (ru) 2008-09-20
CN101014587B (zh) 2013-12-18
MX2007001696A (es) 2007-04-23
US20060122394A1 (en) 2006-06-08
WO2006026135A3 (en) 2006-06-15
ECSP077318A (es) 2007-04-26
CN101014587A (zh) 2007-08-08
AU2005280366A1 (en) 2006-03-09
US20110003813A1 (en) 2011-01-06
NO20071243L (no) 2007-04-27
PE20060620A1 (es) 2006-08-11
SG157399A1 (en) 2009-12-29
US7662830B2 (en) 2010-02-16
EP1786800A2 (en) 2007-05-23
TW200605889A (en) 2006-02-16

Similar Documents

Publication Publication Date Title
CR8992A (es) Analogos de biaril piperazinilpiridina sustituida
NI200900023A (es) Análogos de 2-fenoxi pirimidinona
CR8497A (es) Derivados de azepinoindol como agentes farmaceuticos
MY148461A (en) Heteroaryl amide analogues as p2x7 antagonists
CL2013001073A1 (es) Compuestos derivados de 6-amino-nicotinamidas sustituidas, como moduladores de kcnq2/3; composicion farmaceutica que los comprende, util para el tratamiento y/o profilaxis de trastornos y/o enfermedades seleccionadas de dolor, epilepsia, ansiedad, enfermedades cognitivas, entre otras.
TW200621251A (en) Substituted biaryl quinolin-4-ylamine analogues
MXPA05006123A (es) Analogos de quinazolin-4-ilamina 2-sustituida como moduladores de receptores de capsaicina.
CO6270312A2 (es) Moduladores de gpr40 bifenilo-sustituidos
BRPI0512274A (pt) derivados de piperazina aril-substituìdos
WO2006081388A3 (en) Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues
TW200510373A (en) Substituted quinolin-4-ylamine analogues
UY29478A1 (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
UY31760A (es) Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de leucotrieno a4 hidrolasa
CL2012001031A1 (es) Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros.
ECSP11010956A (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos
DOP2013000102A (es) Moduladores de gpr 119
NI201100183A (es) Antagonistas de ccr3 de arilsulfonamida 2, 5 - disustituida
NI201100185A (es) Antagonistas de ccr3 de arilsulfonamida
HN2011000404A (es) Derivados de enfumafungina y composicion comprendiendo los mismos
CO6280529A2 (es) DERIVADOS DE AMIDA AROMÁTICOS DE ÁCIDO PENTANOICO COMO MODULADORES DE γ - SECRETOSA
CR8825A (es) Metabolitos de indolilalquilamina como ligandos 5- hidroxitriptamina-6
DOP2005000164A (es) Analogos de biaril piperazinil-piridina sustituidos
DE602004007141D1 (de) Aryl-substituierte benzoädüisothiazol-3-ylamin analoga als capsaicinrezeptormodulatoren
TW200510383A (en) Biaryl piperazinyl-pyridine analogues

Legal Events

Date Code Title Description
FC Refusal